Navigation Links
Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
Date:1/8/2014

PRINCETON, N.J., Jan. 8, 2014 /PRNewswire/ -- Agile Therapeutics, Inc., announced today the appointment of Elizabeth Ijeoma Onyemelukwe Garner, M.D., M.P.H., as Chief Medical Officer effective January 6, 2014.  Dr. Garner will be a member of Agile's executive management team and will lead the clinical research, drug safety and medical affairs teams in the clinical development of the Company's product pipeline.

"Elizabeth has prominent expertise in women's health and significant clinical development experience in the pharmaceutical industry and we are very pleased to welcome her as a member of our executive management team," said Al Altomari, Chief Executive Officer of Agile Therapeutics. "Her strong and highly relevant experience overseeing successful clinical trial programs and regulatory approval is the precise expertise we seek to advance our development programs of our innovative hormonal contraceptive treatment option and to drive the long-term growth."

Most recently, Dr. Garner served as Vice President, Women's Health and Preventive Care at Myriad Genetics Laboratories, and managed the women's health clinical research, publication, and Key Opinion Leader (KOL) development program, provided medical and scientific input to the company's marketing and new product strategies, and served as the company's media spokesperson.  Prior to joining Myriad Genetics, she was Senior Director at Abbott (now AbbVie) where she managed the global Phase III clinical development program in endometriosis.  From 2007 to 2011, Dr. Garner served as Director, Vaccines Clinical Research at Merck Research Laboratories where she was a key clinical development leader for the human papillomavirus vaccine program and was instrumental in achieving successful outcomes on important supplemental submissions to the Food and Drug Administration.

"I am extremely pleased to be joining Agile Therapeutics and I look forward to building upon the significant momentum of the clinical development programs and bringing them to a successful outcome," said Dr. Elizabeth Garner. "I look forward to helping the company fulfill its goal of offering women a safe and convenient hormonal option that represents real innovation and fills a critical void in women's contraception."

Prior to entering the pharmaceutical industry, Dr. Garner had several years of experience in academic clinical practice, research and teaching at Harvard Medical School.  She received joint M.D. and M.P.H degrees from Harvard Medical School and the School of Public Health.  Dr. Garner did her residency in obstetrics and gynecology at Brigham and Women's/Massachusetts General Hospitals, her subspecialty fellowship in gynecologic oncology at Brigham and Women's and the Dana Farber Cancer Institute, and received board certification in both general Obstetrics and Gynecology and Gynecologic Oncology.  Dr. Garner is an author on numerous scientific papers published in peer-reviewed journals and has received many awards and honors over the course of her career.

About Agile Therapeutics
Agile Therapeutics is a specialty pharmaceutical company focused on women's health that is currently developing innovative contraceptive products based on Agile's proprietary and patented transdermal technology called Skinfusion®. Skinfusion consists of both an active and a peripheral adhesive system designed to allow stable drug delivery and dependable adhesion over seven days. The Company's lead investigational product, Twirla™(AG200-15), is a once-weekly contraceptive patch designed to provide convenience and compliance that is currently in late stage clinical development. Agile has an additional pipeline of product candidates consisting of innovative contraceptive patch regimens and a progestin-only contraceptive patch (AG890) that utilize Skinfusion.  For more information, please visit http://www.agiletherapeutics.com.

Forward Looking Statements
Certain matters discussed in this press release are "forward-looking statements".  We may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.  In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect, to our product candidates; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products; and other factors, including general economic conditions and regulatory developments, not within the Company's control.  The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements.  The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.


'/>"/>
SOURCE Agile Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSurplus Announces Launch of Depot Service for Agilent and AKTA HPLCs
2. Omnyx Share Their Insight on Agile Software Development for Medical Devices
3. Medical Equipment Suppliers in Good Health - Research Report on Bruker Corporation, Agilent Technologies Inc., General Electric Company, Becton, Dickinson and Co. and Thermo Fisher Scientific Inc.
4. Technical Scrutiny: Thermo Fisher, Agilent Technologies, Laboratory Corp. of America, and PerkinElmer
5. Global Laboratory Analytical Instrument Market 2012-2016: Agilent Technologies, Bruker Corp. and Thermo Fisher Scientific Inc. Dominate the Market
6. Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and Life Technologies
7. Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology
8. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
10. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):